Format

Send to

Choose Destination
See comment in PubMed Commons below
Eur Heart J Acute Cardiovasc Care. 2014 Sep;3(3):246-56. doi: 10.1177/2048872614527838. Epub 2014 Mar 13.

Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial.

Author information

1
Department of Medical Sciences, Cardiology, Uppsala University/Uppsala Clinical Research Center, Uppsala, Sweden claes.held@ucr.uu.se.
2
Duke Clinical Research Institute, Durham, NC, USA.
3
University of Leuven, Leuven, Belgium.
4
Auckland City Hospital, Auckland, New Zealand.
5
University of Alberta, Edmonton, Canada.
6
University of Perugia, Perugia, Italy.
7
Flinders University and Medical Centre, Adelaide, Australia.
8
University of Kentucky, Lexington, KY, USA.
9
Department of Medical Sciences, Cardiology, Uppsala University/Uppsala Clinical Research Center, Uppsala, Sweden.
10
Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.
11
Ufuk University, Ankara, Turkey.
12
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
13
Merck, Whitehouse Station, NJ, USA.
14
Stanford University, Stanford, CA, USA.

Abstract

BACKGROUND:

This study characterized a medically managed population in a non-ST-segment elevation acute coronary syndrome (NSTEACS) cohort and evaluated prognosis and outcomes of vorapaxar vs. placebo.

METHODS:

In the TRACER study, 12,944 NSTEACS patients were treated with standard care and vorapaxar (a novel platelet protease-activated receptor-1 antagonist) or placebo. Of those, 4194 patients (32.4%) did not undergo revascularization during index hospitalization, and 8750 (67.6%) underwent percutaneous coronary intervention or coronary artery bypass grafting. Patients managed medically were heterogeneous with different risk profiles, including 1137 (27.1%) who did not undergo coronary angiography. Patients who underwent angiography but were selected for medical management included those without evidence of significant coronary artery disease (CAD), with prior CAD but no new significant lesions, and with significant lesions who were not treated with revascularization.

RESULTS:

Cardiovascular event rates were highest among those without angiography and lowest in the group with angiography but without CAD. In the medically managed cohort, 2-year primary outcome (cardiovascular death, myocardial infarction, stroke, recurrent ischaemia with rehospitalization, urgent coronary revascularization) event rates were 16.3% with vorapaxar and 17.0% with placebo (HR 0.99, 95% CI 0.83-1.17), with no interaction between drug and management strategy (p=0.75). Key secondary endpoint (cardiovascular death, myocardial infarction, stroke) rates were 13.4% with vorapaxar and 14.9% with placebo (HR 0.89, 95% CI 0.74-1.07), with no interaction (p=0.58). Vorapaxar increased GUSTO moderate/severe bleeding numerically in medically managed patients (adjusted HR 1.46, 95% CI 0.99-2.15).

CONCLUSIONS:

NSTEACS patients who were initially medically managed had a higher risk-factor burden, and one-third had normal coronary arteries. Outcome in the medically managed cohort was significantly related to degree of CAD, highlighting the importance of coronary angiography. Efficacy and safety of vorapaxar appeared consistent with the overall trial results.

KEYWORDS:

Myocardial infarction; platelet receptor blockers; thrombosis

PMID:
24627331
DOI:
10.1177/2048872614527838
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon
    Loading ...
    Support Center